Does the media prefer AGIO or EVMN?

In the previous week, Agios Pharmaceuticals had 9 more articles in the media than Evommune. MarketBeat recorded 11 mentions for Agios Pharmaceuticals and 2 mentions for Evommune. Agios Pharmaceuticals' average media sentiment score of 1.49 beat Evommune's score of 0.89 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KARD or EVMN?

Kardigan has higher earnings, but lower revenue than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Evommune $10M 45.48 -$68.87M -$11.03 N/A

Is KARD or EVMN more profitable?

Kardigan's return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Evommune N/A -62.63% -40.55%

Does the media refer more to KARD or EVMN?

In the previous week, Kardigan had 2 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Kardigan and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat Kardigan's score of 0.44 indicating that Evommune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TSHA or EVMN more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Evommune N/A -62.63% -40.55%

Does the media refer more to TSHA or EVMN?

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 2 articles in the media. Taysha Gene Therapies' average media sentiment score of 1.71 beat Evommune's score of 0.89 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LKFT or EVMN more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Evommune N/A -62.63% -40.55%

Does the media favor LKFT or EVMN?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 2 articles in the media. Evommune's average media sentiment score of 0.89 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.47 indicating that Evommune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IMCR or EVMN?

Immunocore has higher revenue and earnings than Evommune. Immunocore is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 4.64 -$35.51M -$0.37 N/A Evommune $10M 45.48 -$68.87M -$11.03 N/A

Is IMCR or EVMN more profitable?

Evommune has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% Evommune N/A -62.63% -40.55%

Does the media prefer IMCR or EVMN?

In the previous week, Immunocore had 3 more articles in the media than Evommune. MarketBeat recorded 5 mentions for Immunocore and 2 mentions for Evommune. Immunocore's average media sentiment score of 1.15 beat Evommune's score of 0.89 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evommune (EVMN) Competitors

$12.53 -0.13 (-1.01%)

As of 10:04 AM Eastern

Compare

EVMN vs. AGIO, KARD, TSHA, LKFT, and IMCR

Should you buy Evommune stock or one of its competitors? Evommune's main competitors and comparable companies include Agios Pharmaceuticals (AGIO), Kardigan (KARD), Taysha Gene Therapies (TSHA), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Immunocore (IMCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evommune compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Evommune (NYSE:EVMN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

In the previous week, Agios Pharmaceuticals had 9 more articles in the media than Evommune. MarketBeat recorded 11 mentions for Agios Pharmaceuticals and 2 mentions for Evommune. Agios Pharmaceuticals' average media sentiment score of 1.49 beat Evommune's score of 0.89 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals currently has a consensus price target of $41.25, suggesting a potential upside of 22.88%. Evommune has a consensus price target of $41.56, suggesting a potential upside of 231.60%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Evommune has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	37.09	-$412.78M	-$7.01	N/A
Evommune	$10M	45.48	-$68.87M	-$11.03	N/A

Evommune has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Evommune	N/A	-62.63%	-40.55%

Summary

Evommune beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Evommune compare to Kardigan?

Kardigan (NASDAQ:KARD) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Kardigan presently has a consensus target price of $42.25, suggesting a potential upside of 107.82%. Evommune has a consensus target price of $41.56, suggesting a potential upside of 231.60%. Given Evommune's higher possible upside, analysts plainly believe Evommune is more favorable than Kardigan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Kardigan's return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

In the previous week, Kardigan had 2 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Kardigan and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat Kardigan's score of 0.44 indicating that Evommune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan has higher earnings, but lower revenue than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Evommune	$10M	45.48	-$68.87M	-$11.03	N/A

Summary

Evommune beats Kardigan on 5 of the 8 factors compared between the two stocks.

How does Evommune compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 2 articles in the media. Taysha Gene Therapies' average media sentiment score of 1.71 beat Evommune's score of 0.89 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	186.36	-$109M	-$0.42	N/A
Evommune	$10M	45.48	-$68.87M	-$11.03	N/A

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 31.1% of Evommune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Taysha Gene Therapies' return on equity of -56.19% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Evommune	N/A	-62.63%	-40.55%

Taysha Gene Therapies presently has a consensus target price of $12.77, suggesting a potential upside of 128.51%. Evommune has a consensus target price of $41.56, suggesting a potential upside of 231.60%. Given Evommune's higher possible upside, analysts plainly believe Evommune is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Taysha Gene Therapies beats Evommune on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Evommune. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.50	$363.05M	-$1.41	N/A
Evommune	$10M	45.48	-$68.87M	-$11.03	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 2 articles in the media. Evommune's average media sentiment score of 0.89 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.47 indicating that Evommune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 31.1% of Evommune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $30.67, suggesting a potential upside of 7.38%. Evommune has a consensus price target of $41.56, suggesting a potential upside of 231.60%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Evommune beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 14 factors compared between the two stocks.

How does Evommune compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

In the previous week, Immunocore had 3 more articles in the media than Evommune. MarketBeat recorded 5 mentions for Immunocore and 2 mentions for Evommune. Immunocore's average media sentiment score of 1.15 beat Evommune's score of 0.89 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 56.38%. Evommune has a consensus target price of $41.56, indicating a potential upside of 231.60%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Evommune has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Evommune	N/A	-62.63%	-40.55%

Immunocore has higher revenue and earnings than Evommune. Immunocore is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.64	-$35.51M	-$0.37	N/A
Evommune	$10M	45.48	-$68.87M	-$11.03	N/A

Summary

Immunocore beats Evommune on 8 of the 15 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$456.74M	$3.94B	$7.16B	$23.95B
Dividend Yield	N/A	3.61%	2.54%	3.72%
P/E Ratio	-1.14	11.87	272.62	29.62
Price / Sales	45.48	1,336.63	621.98	19.12
Price / Cash	N/A	44.06	28.78	19.75
Price / Book	1.92	17.07	11.13	4.79
Net Income	-$68.87M	-$22.72M	$3.47B	$1.07B
7 Day Performance	-9.12%	-3.17%	-1.66%	-1.49%
1 Month Performance	11.54%	10.47%	7.09%	1.05%
1 Year Performance	N/A	52.98%	23.37%	12.35%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.9241 of 5 stars	$12.53 -1.0%	$41.56 +231.6%	N/A	$456.74M	$10M	N/A	45
AGIO Agios Pharmaceuticals	2.7189 of 5 stars	$34.28 +0.9%	$41.25 +20.3%	-10.7%	$2.03B	$54.03M	N/A	390	Positive News
KARD Kardigan	3.6919 of 5 stars	$20.80 -1.8%	$42.25 +103.1%	N/A	$1.98B	N/A	N/A	N/A	High Trading Volume
TSHA Taysha Gene Therapies	3.0428 of 5 stars	$5.96 -1.0%	$12.77 +114.2%	+94.9%	$1.96B	$9.77M	N/A	180	Positive News
LKFT Lakefront Biotherapeutics American Depositary Shares	1.2543 of 5 stars	$29.44 +1.0%	$30.67 +4.2%	-9.4%	$1.92B	$1.26B	N/A	1,310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. AGIO, KARD, TSHA, LKFT, and IMCR

How does Evommune compare to Agios Pharmaceuticals?

Summary

How does Evommune compare to Kardigan?

Summary

How does Evommune compare to Taysha Gene Therapies?

Summary

How does Evommune compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Evommune compare to Immunocore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. AGIO, KARD, TSHA, LKFT, and IMCR

How does Evommune compare to Agios Pharmaceuticals?

Does the media prefer AGIO or EVMN?

Do analysts rate AGIO or EVMN?

Which has preferable earnings and valuation, AGIO or EVMN?

Is AGIO or EVMN more profitable?

Summary

How does Evommune compare to Kardigan?

Do analysts rate KARD or EVMN?

Is KARD or EVMN more profitable?

Does the media refer more to KARD or EVMN?

Which has higher earnings and valuation, KARD or EVMN?

Summary

How does Evommune compare to Taysha Gene Therapies?

Does the media refer more to TSHA or EVMN?

Which has stronger valuation and earnings, TSHA or EVMN?

Do insiders & institutionals hold more shares of TSHA or EVMN?

Is TSHA or EVMN more profitable?

Do analysts recommend TSHA or EVMN?

Summary

How does Evommune compare to Lakefront Biotherapeutics American Depositary Shares?

Which has preferable earnings & valuation, LKFT or EVMN?

Does the media favor LKFT or EVMN?

Is LKFT or EVMN more profitable?

Do institutionals & insiders hold more shares of LKFT or EVMN?

Do analysts recommend LKFT or EVMN?

Summary

How does Evommune compare to Immunocore?

Does the media prefer IMCR or EVMN?

Do insiders and institutionals believe in IMCR or EVMN?

Do analysts recommend IMCR or EVMN?

Is IMCR or EVMN more profitable?

Which has better valuation & earnings, IMCR or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools